Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017 (2017), Article ID 3625729, 19 pages
https://doi.org/10.1155/2017/3625729
Research Article

Gd3+-Asparagine-Anionic Linear Globular Dendrimer Second-Generation G2 Complexes: Novel Nanobiohybrid Theranostics

1Department of Radiopharmacy and Medicinal Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2Drug Applied Research Center and Students’ Research Committee, Tabriz University of Medical Science, Tabriz, Iran
3Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
4Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran
5Department of Medical Nanotechnology, School of Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran
6Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Seyed Ataollah Sadat Shandiz; ri.ca.btcuai@zidnahstadas.ata and Mehdi Shafiee Ardestani; ri.ca.smut@inatsedraeeifahsri

Received 13 December 2016; Accepted 15 March 2017; Published 26 September 2017

Academic Editor: Lei Zhu

Copyright © 2017 Nasim Hashempour Alamdari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Mousavi, M. M. Gouya, R. Ramazani, M. Davanlou, N. Hajsadeghi, and Z. Seddighi, “Cancer incidence and mortality in Iran,” Annals of Oncology, vol. 20, no. 3, pp. 556–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Darvish Mohamadi, M. Amanlou, N. Ghalandarlaki, B. Mehravi, M. Shafiee Ardestani, and P. Yaghmaei, “Gd3+-DTPA-meglumine-anionic linear globular dendrimer G1: novel nanosized low toxic tumor molecular MR imaging agent,” ISRN Pharmaceutics, vol. 2013, 14 pages, 2013. View at Publisher · View at Google Scholar
  3. B. R. Cassileth and G. Deng, “Complementary and alternative therapies for cancer,” Oncologist, vol. 9, no. 1, pp. 80–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Denecke, B. Rau, K-T. Hoffmann et al., “Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?” European Radiology, vol. 15, no. 8, pp. 1658–1666, 2005. View at Publisher · View at Google Scholar
  5. J. Kalita and U. Misra, “Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis,” Journal of the Neurological Sciences, vol. 174, no. 1, pp. 3–8, 2000. View at Publisher · View at Google Scholar
  6. W. H. Theodore, R. Dorwart, M. Holmes, R. J. Porter, and G. DiChiro, “Neuroimaging in refractory partial seizures: Comparison of PET, CT, and MRI,” Neurology, vol. 36, no. 6, pp. 750–759, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Cummings, T. Keane, B. O’sullivan, C. Wong, and C. Catton, “Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C,” International Journal of Radiation Oncology, Biology, Physics, vol. 21, no. 5, pp. 1115–1125, 1991. View at Publisher · View at Google Scholar
  8. C. K. Kuhl, S. Schrading, H. B. Bieling et al., “MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study,” Lancet, vol. 370, no. 9586, pp. 485–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Grobner, “Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?” Nephrology Dialysis Transplantation, vol. 21, no. 4, pp. 1104–1108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Caravan, “Strategies for increasing the sensitivity of gadolinium based MRI contrast agents,” Chemical Society Reviews, vol. 35, no. 6, pp. 512–523, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. E. R. Gillies and J. M. Frechet, “Dendrimers and dendritic polymers in drug delivery,” Drug Discov Today, vol. 10, no. 1, pp. 35–43, 2005. View at Publisher · View at Google Scholar
  12. S. Aime, C. Cabella, S. Colombatto, S. Geninatti Crich, E. Gianolio, and F. Maggioni, “Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations,” Journal of Magnetic Resonance Imaging, vol. 16, no. 4, pp. 394–406, 2002. View at Publisher · View at Google Scholar
  13. A. Assadi, V. S. Najafabadi, S. A. S. Shandiz et al., “Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity,” OncoTargets and Therapy, vol. 7, no. 9, pp. 5531–5543, 2016. View at Publisher · View at Google Scholar
  14. U. Boas, J. B. Christensen, and P. M. Heegaard, “Dendrimers: design, synthesis and chemical properties,” Journal of Materials Chemistry, vol. 16, no. 38, pp. 3785–3798, 2006. View at Publisher · View at Google Scholar
  15. A. K. Patri, J. F. Kukowska-Latallo, and Baker Jr., “Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex,” Advanced Drug Delivery Reviews, vol. 57, no. 15, pp. 2203–2214, 2005. View at Publisher · View at Google Scholar
  16. K. Madaan, S. Kumar, N. Poonia, V. Lather, and D. Pandita, “Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues,” Journal of Pharmacy and Bioallied Sciences, vol. 6, no. 3, pp. 139–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. B. Pryor, B. J. Harper, and S. L. Harper, “Comparative toxicological assessment of PAMAM and thiophosphoryl dendrimers using embryonic zebrafish,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 1947–1956, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Aznavoorian, A. N. Murphy, W. G. Stetler‐Stevenson, and L. A. Liotta, “Molecular aspects of tumor cell invasion and metastasis,” Cancer, vol. 71, no. 4, pp. 1368–1383, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Haririan, M. S. Alavidjeh, M. R. Khorramizadeh, M. S. Ardestani, Z. Z. Ghane, and H. Namazi, “Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines,” International Journal of Nano Medicine, vol. 5, article 63, 2010. View at Google Scholar
  20. M. S. Alavidjeh, I. Haririan, M. R. Khorramizadeh, Z. Z. Ghane, M. S. Ardestani, and H. Namazi, “Anionic linear-globular dendrimers: biocompatible hybrid materials with potential uses in nanomedicine,” Journal of Materials Science: Materials in Medicine, vol. 21, no. 4, pp. 1121–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Mohammadi, M. Amanlou, S. E. S. Ebrahimi et al., “Cellular uptake, imaging and pathotoxicological studies of a novel Gd[III]–DO3A-butrol nano-formulation,” RSC Advances, vol. 4, no. 86, pp. 45984–45994, 2014. View at Publisher · View at Google Scholar
  22. H. Hifumi, S. Yamaoka, A. Tanimoto, D. Citterio, and K. Suzuki, “Gadolinium-based hybrid nanoparticles as a positive MR contrast agent,” Journal of the American Chemical Society, vol. 128, no. 47, pp. 15090-15091, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Artemov, “Molecular magnetic resonance imaging with targeted contrast agents,” Journal of Cellular Biochemistry, vol. 90, no. 3, pp. 518–524, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Konda, M. Aref, S. Wang, M. Brechbiel, and E. C. Wiener, “Specific targeting of folate–dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts,” Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 12, no. 2-3, pp. 104–113, 2001. View at Publisher · View at Google Scholar
  25. M. A. Medina, F. Sánchez-Jiménez, J. Márquez, A. Rodríguez Quesada, and I. de Castro Núñez, “Relevance of glutamine metabolism to tumor cell growth,” Molecular and Cellular Biochemistry, vol. 113, no. 1, pp. 1–15, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. B. C. Fuchs and B. P. Bode, “Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?” Seminars in Cancer Biology, vol. 15, no. 4, pp. 254–266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Abdul and N. Hoosein, “N-methyl-D-aspartate receptor in human prostate cancer,” Journal of Membrane Biology, vol. 205, no. 3, pp. 125–128, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Flacke, S. Fischer, M. J. Scott et al., “Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques,” Circulation, vol. 104, no. 11, pp. 1280–1285, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Dutton, A. N. Massoura, T. J. Dover, N. A. Andrews, and N. M. Barnes, “Identification and functional significance of N-glycosylation of the 5-ht5A receptor,” Neurochemistry International, vol. 52, no. 3, pp. 419–425, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. N. HashempourAlamdari, Synthesis and evaluation of Gd3+-Asparagine- Anionic Linear Globular Dendrimer Second Generation G2 as Novel MRI Agent [PhD. thesis], 2013, Supervised by Dr. Mehdi Shafiee Ardestani 2013-1015.